studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 231A
respectively. The median (IQR) time intervals were 46.5 (62)
and 47.5 (87) days between MRE and biopsy and between
ARFI and biopsy, respectively. For diagnosing any fibrosis,
MRE had an area under ROC curve (AUROC) of 0.799 (95%
CI, 0.723-0.875), which was significantly (p=0.012) higher
than ARFI, which had an AUROC of 0.664 (95% CI, 0.568-
0.760). The AUROCs of MRE for diagnosing ≥ stages 2, 3,
and 4 fibrosis were 0.885 (95% CI, 0.816-0.953), 0.934
(95% CI, 0.863-1.000), and 0.882 (95% CI, 0.729-1.000),
and those for ARFI were 0.848 (95% CI, 0.776-0.921), 0.896
(95% CI, 0.824-0.968), and 0.862 (95% CI, 0.721-1.000).
MRE had a higher AUROC than ARFI for discriminating dichotomized
fibrosis stages at every dichotomization cutpoint, but
the difference in AUROC was smaller as the dichotomization
cutpoint increased. Conclusion: In a head-to-head comparison
and using contemporaneous liver biopsy as the gold standard,
MRE provides significantly higher diagnostic accuracy than
ARFI for diagnosing any fibrosis in NAFLD patients.
Disclosures:
Claude B. Sirlin - Grant/Research Support: GE, Pfizer, Bayer, Guerbet, Siemens
Rohit Loomba - Advisory Committees or Review Panels: Galmed Inc, Tobira Inc,
Arrowhead Research Inc; Consulting: Gilead Inc, Corgenix Inc, Janssen and
Janssen Inc, Zafgen Inc, Celgene Inc, Alnylam Inc, Inanta Inc, Deutrx Inc; Grant/
Research Support: Daiichi Sankyo Inc, AGA, Merck Inc, Promedior Inc, Kinemed
Inc, Immuron Inc, Adheron Inc
The following authors have nothing to disclose: Jeffrey Y. Cui, Elhamy Heba,
Carolyn Hernandez, William Haufe, Jonathan Hooker
46
The predictive value of 13 C-Methacetin breath test (MBT)
for liver transplantation (LT) and death: a seven year
follow-up study of 206 chronic hepatitis C patients
Oliver Goetze 2,1 , Monika Breuer 1 , Andreas Geier 2,1 , Michael
Fried 1 , Achim Weber 4 , Yaron Ilan 3 , Beat Mullhaupt 1 ; 1 Department
of Gastroenterology & Hepatology, University Hospital Zurich,
Zurich, Switzerland; 2 Division of Hepatology, University Hospital
Würzburg, Würzburg, Germany; 3 Department of Medicine,
Hebrew University-Hadassah Medical Center, Jerusalem, Israel;
4 Institute of Surgical Pathology, University Hospital Zurich, Zurich,
Switzerland
In patients with chronic liver disease, currently used biomarkers
demonstrate limited mid- to long-term predictive values to
forecast deterioration of liver function leading to liver transplantation
(LT) or liver related death. Aim: To determine the
predictive value of the 13 C-Methacetin Breath Test (MBT)
(BreathID ® ; Exalenz) in forseeing deterioration of liver function
leading to LT and/or death in patients with chronic HCV infection.
Methods: A total of 265 chronic HCV infected patients
were enrolled, out of which 206 patients (71 females) without
co-infections and/or liver comorbidities were considered for
this analysis. The average BMI was 24.8 kg/m 2 (SD 4.0 kg/
m 2 ), 183 patients underwent liver biopsy and ISHAK scoring
and 196 patients underwent MBT. 13 C-Methacetin peak percent
dose recovery rate (PDR-Peak) was used as determinant
parameter for this analysis. Patients were followed for up to
7 years according to standard of care. During the course of
follow-up some patients underwent antiviral treatment as part of
routine patient management. Primary analysis was performed
on all patients up to one of the following: liver-transplantation,
death or response to antiviral treatment, resulting in 161
and 158 patients with biopsy and/or MBT results respectively.
Predictive value was assessed using ROC curve and survival
analyses. Results: In seven years follow up, PDR-Peak, using
cut-off of 20%/h, predicted LT and/or death with HR=12.07
(95%CI 3.48;41.84),p